{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:18:49Z","timestamp":1778876329018,"version":"3.51.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100013355","name":"Center for Protein Therapeutics, University at Buffalo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013355","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s11095-026-04044-0","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T21:08:41Z","timestamp":1773868121000},"page":"1089-1099","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Binding Kinetics Can Explain Linear and Nonlinear Pharmacokinetics of Dipeptidyl Peptidase-IV Inhibitors Within a Single Target-Mediated Framework"],"prefix":"10.1007","volume":"43","author":[{"given":"Adam","family":"Elalem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4311-1133","authenticated-orcid":false,"given":"Mfonabasi E.","family":"Ette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4848-0440","authenticated-orcid":false,"given":"Donald E.","family":"Mager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"issue":"6","key":"4044_CR1","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/j.1552-4604.1989.tb03369.x","volume":"29","author":"WJ Jusko","year":"1989","unstructured":"Jusko WJ. Pharmacokinetics of capacity-limited systems. J Clin Pharmacol. 1989;29(6):488\u201393.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"4044_CR2","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/clpt.1994.134","volume":"56","author":"G Levy","year":"1994","unstructured":"Levy G. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther. 1994;56(3):248\u201352.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"4044_CR3","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1023\/A:1014414520282","volume":"28","author":"DE Mager","year":"2001","unstructured":"Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28(6):507\u201332.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"4044_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/jcph.804","volume":"57","author":"G An","year":"2017","unstructured":"An G. Small-Molecule Compounds Exhibiting Target-Mediated Drug Disposition (TMDD): A Minireview. J Clin Pharmacol. 2017;57(2):137\u201350.","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"4044_CR5","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/j.drudis.2018.06.010","volume":"23","author":"DA Smith","year":"2018","unstructured":"Smith DA, van Waterschoot RAB, Parrott NJ, Olivares-Morales A, Lav\u00e9 T, Rowland M. Importance of target-mediated drug disposition for small molecules. Drug Discov Today. 2018;23(12):2023\u201330.","journal-title":"Drug Discov Today"},{"key":"4044_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00389","volume":"10","author":"B Gallwitz","year":"2019","unstructured":"Gallwitz B. Clinical use of DPP4I inhibitors. Front Endocrinol (Lausanne). 2019;10:389.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"4044_CR7","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1042\/CS20180031","volume":"132","author":"K Kanasaki","year":"2018","unstructured":"Kanasaki K. The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin. Clin Sci Lond. 2018;132(4):489\u2013507.","journal-title":"Clin Sci Lond"},{"issue":"4","key":"4044_CR8","first-page":"298","volume":"15","author":"V Gupta","year":"2011","unstructured":"Gupta V, Kalra S. Choosing a gliptin. J Endocrinol Metab. 2011;15(4):298\u2013308.","journal-title":"J Endocrinol Metab"},{"issue":"23","key":"4044_CR9","doi-asserted-by":"publisher","first-page":"3982","DOI":"10.2174\/092986712802002491","volume":"19","author":"Y Liu","year":"2012","unstructured":"Liu Y, Hu Y, Liu T. Recent advances in non-peptidomimetic dipeptidyl peptidase 4 inhibitors: medicinal chemistry and preclinical aspects. Curr Med Chem. 2012;19(23):3982\u201399.","journal-title":"Curr Med Chem"},{"issue":"1","key":"4044_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1463-1326.2010.01306.x","volume":"13","author":"CF Deacon","year":"2011","unstructured":"Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab. 2011;13(1):7\u201318.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"4044_CR11","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1517\/17425255.2014.907274","volume":"10","author":"TD Filippatos","year":"2014","unstructured":"Filippatos TD, Athyros VG, Elisaf MS. The pharmacokinetic considerations and adverse effects of DPP4I inhibitors [corrected]. Expert Opin Drug Metab Toxicol. 2014;10(6):787\u2013812.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"11","key":"4044_CR12","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/s41574-020-0399-8","volume":"16","author":"CF Deacon","year":"2020","unstructured":"Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020;16(11):642\u201353.","journal-title":"Nat Rev Endocrinol"},{"key":"4044_CR13","unstructured":"Clinical Pharmacology Biopharmaceutics Review for linagliptin. NDA 201280, 201280Orig1s000. U.S. Food and Drug Administration; 2011. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/201280Orig1s000ClinPharmR.pdf. Accessed 9 Feb 2026."},{"issue":"1","key":"4044_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.12793\/tcp.2020.28.e4","volume":"28","author":"N Gu","year":"2020","unstructured":"Gu N, Park SI, Chung H, Jin X, Lee S, Kim TE. Possibility of pharmacokinetic drug interaction between a DPP4I inhibitor and a SGLT2 inhibitor. Transl Clin Pharmacol. 2020;28(1):17\u201333.","journal-title":"Transl Clin Pharmacol"},{"issue":"7","key":"4044_CR15","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s40265-019-01086-0","volume":"79","author":"A Ceriello","year":"2019","unstructured":"Ceriello A, De Nigris V, Iijima H, Matsui T, Gouda M. The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice. Drugs. 2019;79(7):733\u201350.","journal-title":"Drugs"},{"issue":"8","key":"4044_CR16","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/j.1463-1326.2010.01212.x","volume":"12","author":"AJ Scheen","year":"2010","unstructured":"Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010;12(8):648\u201358.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"4044_CR17","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2165\/11598080-000000000-00000","volume":"51","author":"YL He","year":"2012","unstructured":"He YL. Clinical pharmacokinetics and pharmacodynamics of vildagliptin. Clin Pharmacokinet. 2012;51(3):147\u201362.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"4044_CR18","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1002\/jcph.2043","volume":"62","author":"MA Butrovich","year":"2022","unstructured":"Butrovich MA, Tang W, Boulton DW, Nolin TD, Sharma P. Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Impact of Chronic Kidney Disease on CYP3A4-Mediated Metabolism of Saxagliptin. J Clin Pharmacol. 2022;62(8):1018\u201329.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"4044_CR19","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/bdd.1928","volume":"36","author":"Y Nakamaru","year":"2015","unstructured":"Nakamaru Y, Emoto C, Shimizu M, Yamazaki H. Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling. Biopharm Drug Dispos. 2015;36(3):148\u201362.","journal-title":"Biopharm Drug Dispos"},{"key":"4044_CR20","unstructured":"Clinical Pharmacology Biopharmaceutics Review for alogliptin. NDA 022271, 022271Orig1s000. U.S. Food and Drug Administration; 2012. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/022271Orig1s000ClinPharmR.pdf. Accessed 9 Feb 2026."},{"issue":"1","key":"4044_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1365-2125.2008.03148.x","volume":"66","author":"GC Mistry","year":"2008","unstructured":"Mistry GC, Bergman AJ, Zheng W, Hreniuk D, Zinny MA, Gottesdiener KM, et al. Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects. Br J Clin Pharmacol. 2008;66(1):36\u201342.","journal-title":"Br J Clin Pharmacol"},{"issue":"16","key":"4044_CR22","doi-asserted-by":"publisher","first-page":"7466","DOI":"10.1021\/acs.jmedchem.6b00475","volume":"59","author":"G Schnapp","year":"2016","unstructured":"Schnapp G, Klein T, Hoevels Y, Bakker RA, Nar H. Comparative Analysis of Binding Kinetics and Thermodynamics of Dipeptidyl Peptidase-4 Inhibitors and Their Relationship to Structure. J Med Chem. 2016;59(16):7466\u201377.","journal-title":"J Med Chem"},{"issue":"2","key":"4044_CR23","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.bbrc.2013.03.010","volume":"434","author":"M Nabeno","year":"2013","unstructured":"Nabeno M, Akahoshi F, Kishida H, Miyaguchi I, Tanaka Y, Ishii S, et al. A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. Biochem Biophys Res Commun. 2013;434(2):191\u20136.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"4044_CR24","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-020-00481-w","volume":"22","author":"N Wu","year":"2020","unstructured":"Wu N, An G. Incorporating pharmacological target-mediated drug disposition (TMDD) in a whole-body physiologically based pharmacokinetic (PBPK) model of linagliptin in rat and scale-up to human. AAPS J. 2020;22(6):125.","journal-title":"AAPS J"},{"issue":"10","key":"4044_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70047","volume":"17","author":"R Nakamura","year":"2024","unstructured":"Nakamura R, Yoshikado T, Aoki Y, Sugiyama Y, Chiba K. Elucidation of DPP-4 involvement in systemic distribution and renal reabsorption of linagliptin by PBPK modeling with a cluster Gauss-Newton method. Clin Transl Sci. 2024;17(10):e70047.","journal-title":"Clin Transl Sci"},{"issue":"8","key":"4044_CR26","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1177\/0091270009356444","volume":"50","author":"S Retlich","year":"2010","unstructured":"Retlich S, Duval V, Graefe-Mody U, Jaehde U, Staab A. Impact of target-mediated drug disposition on linagliptin pharmacokinetics and DPP4I inhibition in type 2 diabetic patients. J Clin Pharmacol. 2010;50(8):873\u201385.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"4044_CR27","first-page":"708","volume":"16","author":"Y Tadayasu","year":"2013","unstructured":"Tadayasu Y, Sarashina A, Tsuda Y, Tatami S, Friedrich C, Retlich S, et al. Population pharmacokinetic\/pharmacodynamic analysis of the DPP4I inhibitor linagliptin in Japanese patients with type 2 diabetes mellitus. J Pharm Sci. 2013;16(5):708\u201321.","journal-title":"J Pharm Sci"},{"issue":"3","key":"4044_CR28","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/j.1365-2125.2011.04108.x","volume":"73","author":"CB Landersdorfer","year":"2012","unstructured":"Landersdorfer CB, He YL, Jusko WJ. Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV. Br J Clin Pharmacol. 2012;73(3):391\u2013401.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"4044_CR29","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00228-016-2175-1","volume":"73","author":"C Dudkowski","year":"2017","unstructured":"Dudkowski C, Tsai M, Liu J, Zhao Z, Schmidt E, Xie J. The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus. Eur J Clin Pharmacol. 2017;73(3):279\u201388.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"4044_CR30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/bcpt.12068","volume":"113","author":"BH Kim","year":"2013","unstructured":"Kim BH, Kim SE, Kang D, Lim KS, Kim JR, Jang IJ, et al. Pharmacokinetic-pharmacodynamic modelling of biomarker response to sitagliptin in healthy volunteers. Basic Clin Pharmacol Toxicol. 2013;113(2):113\u201325.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"3","key":"4044_CR31","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1124\/dmd.108.023002","volume":"37","author":"H He","year":"2009","unstructured":"He H, Tran P, Yin H, Smith H, Flood D, Kramp R, et al. Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs. Drug Metab Dispos. 2009;37(3):545\u201354.","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"4044_CR32","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1177\/0091270007304313","volume":"47","author":"G Sunkara","year":"2007","unstructured":"Sunkara G, Sabo R, Wang Y, He YL, Campestrini J, Rosenberg M, et al. Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. J Clin Pharmacol. 2007;47(9):1152\u20138.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"4044_CR33","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1177\/0091270006299137","volume":"47","author":"YL He","year":"2007","unstructured":"He YL, Wang Y, Bullock JM, Deacon CF, Holst JJ, Dunning BE, et al. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol. 2007;47(5):633\u201341.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"4044_CR34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1211\/jpp.61.01.0008","volume":"61","author":"H Fuchs","year":"2009","unstructured":"Fuchs H, Tillement JP, Urien S, Greischel A, Roth W. Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans. J Pharm Pharmacol. 2009;61(1):55\u201362.","journal-title":"J Pharm Pharmacol"},{"issue":"8","key":"4044_CR35","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/bdd.676","volume":"30","author":"S Retlich","year":"2009","unstructured":"Retlich S, Withopf B, Greischel A, Staab A, Jaehde U, Fuchs H. Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356)--investigations in DPP4I deficient and wildtype rats. Biopharm Drug Dispos. 2009;30(8):422\u201336.","journal-title":"Biopharm Drug Dispos"},{"key":"4044_CR36","unstructured":"Clinical Pharmacology Biopharmaceutics Review for saxagliptin. NDA 022350, 022350s000. U.S. Food and Drug Administration; 2009. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/022350s000_ClinPharmR_P1.pdf. Accessed 9 Feb 2026."},{"key":"4044_CR37","unstructured":"Tenelia\u00ae (teneligliptin), Common Technical Document 2012. http:\/\/www.pmda.go.jp\/drugs\/2012\/P201200070\/400315000_22400AMX00728_K102_2.pdf. Accessed 15 Nov 2018."},{"issue":"3","key":"4044_CR38","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.clinthera.2008.03.005","volume":"30","author":"R Christopher","year":"2008","unstructured":"Christopher R, Covington P, Davenport M, Fleck P, Mekki QA, Wann ER, et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther. 2008;30(3):513\u201327.","journal-title":"Clin Ther"},{"issue":"6","key":"4044_CR39","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.clpt.2005.09.002","volume":"78","author":"GA Herman","year":"2005","unstructured":"Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005;78(6):675\u201388.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"4044_CR40","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1054\/bjoc.2000.1410","volume":"83","author":"OJ Cordero","year":"2000","unstructured":"Cordero OJ, Ayude D, Nogueira M, Rodriguez-Berrocal FJ, de la Cadena MP. Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer. Br J Cancer. 2000;83(9):1139\u201346.","journal-title":"Br J Cancer"},{"issue":"6","key":"4044_CR41","first-page":"673","volume":"19","author":"M Cuchacovich","year":"2001","unstructured":"Cuchacovich M, Gatica H, Pizzo SV, Gonzalez-Gronow M. Characterization of human serum dipeptidyl peptidase IV (CD26) and analysis of its autoantibodies in patients with rheumatoid arthritis and other autoimmune diseases. Clin Exp Rheumatol. 2001;19(6):673\u201380.","journal-title":"Clin Exp Rheumatol"},{"key":"4044_CR42","doi-asserted-by":"publisher","first-page":"113557","DOI":"10.1016\/j.ab.2019.113557","volume":"592","author":"K Divya","year":"2020","unstructured":"Divya K, Vivek HK, Priya BS, NanjundaSwamy S. Rapid detection of DPP-IV activity in porcine serum: a fluorospectrometric assay. Anal Biochem. 2020;592:113557.","journal-title":"Anal Biochem"},{"issue":"6","key":"4044_CR43","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.clinthera.2010.06.004","volume":"32","author":"A Sarashina","year":"2010","unstructured":"Sarashina A, Sesoko S, Nakashima M, Hayashi N, Taniguchi A, Horie Y, et al. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects. Clin Ther. 2010;32(6):1188\u2013204.","journal-title":"Clin Ther"},{"issue":"7","key":"4044_CR44","doi-asserted-by":"publisher","first-page":"577","DOI":"10.2165\/00003088-200746070-00003","volume":"46","author":"YL He","year":"2007","unstructured":"He YL, Serra D, Wang Y, Campestrini J, Riviere GJ, Deacon CF, et al. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet. 2007;46(7):577\u201388.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"4044_CR45","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.clinthera.2008.03.004","volume":"30","author":"P Covington","year":"2008","unstructured":"Covington P, Christopher R, Davenport M, Fleck P, Mekki QA, Wann ER, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther. 2008;30(3):499\u2013512.","journal-title":"Clin Ther"},{"issue":"6-7","key":"4044_CR46","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/0278-6915(86)90170-5","volume":"24","author":"JR Gillette","year":"1986","unstructured":"Gillette JR. On the role of pharmacokinetics in integrating results from in vivo and in vitro studies. Food Chem Toxicol. 1986;24(6\u20137):711\u201320.","journal-title":"Food Chem Toxicol"},{"issue":"5","key":"4044_CR47","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10928-012-9260-6","volume":"39","author":"LA Peletier","year":"2012","unstructured":"Peletier LA, Gabrielsson J. Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification. J Pharmacokinet Pharmacodyn. 2012;39(5):429\u201351.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"4044_CR48","doi-asserted-by":"publisher","first-page":"E181","DOI":"10.1208\/aapsj0902020","volume":"9","author":"AK Abraham","year":"2007","unstructured":"Abraham AK, Krzyzanski W, Mager DE. Partial derivative-based sensitivity analysis of models describing target-mediated drug disposition. AAPS J. 2007;9(2):E181\u20139.","journal-title":"AAPS J"},{"key":"4044_CR49","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3389\/fendo.2019.00505","volume":"10","author":"J Sarkar","year":"2019","unstructured":"Sarkar J, Nargis T, Tantia O, Ghosh S, Chakrabarti P. Increased plasma dipeptidyl peptidase-4 (DPP4) activity is an obesity-independent parameter for glycemic deregulation in type 2 diabetes patients. Front Endocrinol (Lausanne). 2019;10:505.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"4044_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/jpet.118.250134","volume":"367","author":"X Li","year":"2018","unstructured":"Li X, Jusko WJ, Cao Y. Role of interstitial fluid turnover on target suppression by therapeutic biologics using a minimal physiologically based pharmacokinetic model. J Pharmacol Exp Ther. 2018;367(1):1\u20138.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"4044_CR51","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1124\/dmd.112.048470","volume":"41","author":"N Ishiguro","year":"2013","unstructured":"Ishiguro N, Shimizu H, Kishimoto W, Ebner T, Schaefer O. Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods. Drug Metab Dispos. 2013;41(1):149\u201358.","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"4044_CR52","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1124\/dmd.123.001344","volume":"51","author":"Y Sugiyama","year":"2023","unstructured":"Sugiyama Y, Aoki Y. A 20-year research overview: quantitative prediction of hepatic clearance using the in vitro-in vivo extrapolation approach based on physiologically based pharmacokinetic modeling and extended clearance concept. Drug Metab Dispos. 2023;51(9):1067\u201376.","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"4044_CR53","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1016\/j.xphs.2020.03.031","volume":"109","author":"A Sarashina","year":"2020","unstructured":"Sarashina A, Chiba K, Tatami S, Kato Y. Physiologically based pharmacokinetic model of the DPP-4 inhibitor linagliptin to describe its nonlinear pharmacokinetics in humans. J Pharm Sci. 2020;109(7):2336\u201344.","journal-title":"J Pharm Sci"},{"issue":"1","key":"4044_CR54","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11095-019-2723-3","volume":"37","author":"AK Volz","year":"2019","unstructured":"Volz AK, Dingemanse J, Krause A, Lehr T. Target-mediated population pharmacokinetic modeling of endothelin receptor antagonists. Pharm Res. 2019;37(1):2.","journal-title":"Pharm Res"},{"issue":"8","key":"4044_CR55","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/BF03261927","volume":"51","author":"LK Golightly","year":"2012","unstructured":"Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012;51(8):501\u201314.","journal-title":"Clin Pharmacokinet"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04044-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04044-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04044-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:02:06Z","timestamp":1778875326000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04044-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4044"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04044-0","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"assertion":[{"value":"19 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no conflicts of interest that could be perceived as influencing this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}